







an Open Access Journal by MDPI

The Landscape of Transcriptomic Diversity in Oncology

Guest Editors:

Dr. Osamu Ishibashi

Graduate School of Agriculture, Osaka Metropolitan University, 1-1 Gakuencho, Naka-ku, Sakai 599-8531, Japan

Dr. Tomoo Jikuzono

Department of Endocrine Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan

Deadline for manuscript submissions:

30 August 2024

Message from the Guest Editors

Dear Colleagues,

Recently, the development of transcriptome analyses has been drastically accelerated, which is largely depends on the improved performance of next-generation sequencing. Big data collected from the analyses have not only provided information about aberrant gene expression in various cancer types but also enabled to discover thousands of the novel splice variants of annotated transcripts and unannotated long non-coding RNAs, providing new sources for identification of clinical biomarkers and druggable targets. Especially, cancer-related transcripts have attracted attention because there are still few cancer biomarkers and drugs with satisfactory effectiveness. In this Special Issue category, we highlight the landscape of transcriptomic diversity in oncology

Dr. Osamu Ishibashi Dr. Tomoo Jikuzono *Guest Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us